
Biotechnology & ‘Fog of Valuation’ savant
| Platform | Pricing | Freemium | Publishes | Daily | |
|---|---|---|---|---|---|
| Issues | 201 | Founded | 2 years ago | Last Issue | 3 days ago |
| Active | |||||

In this Video Companion, we step back from several recent Biotech Tape Checks and ask a broader question: What is the biotechnology market trying to tell us?
Rather than reviewing individual headlines or company-specific events, we connect...
As we begin the second half of 2026, we believe it is worthwhile to pause and look backward before looking ahead.
One of the core principles of the Biotech Capital Compass has always been that good investing requires more than identifying...
When compelling science meets the harder question of commercial execution.
This edition of The Investor Exchange examines PolyPid (Nasdaq: PYPD), a subscriber-suggested company developing D-PLEX100 for the prevention of surgical site infec...
Every Sunday, I spend a little time trying to answer a question that is deceptively simple.
Share prices rarely move because of a single event. More often, they reflect thousands of i...
We have increased the frequency of our Biotech Tape Check series in recent months. As volatility across equity markets, interest rates, and global policy continues to rise, we believe it is important to perio...
Subscribers, engagement, traffic and sponsorship for The Biotech Capital Compass.
| Subscribers | Engagement | 72 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
The writers behind this newsletter.
Biotech Capital Compass breaks down complex biotech stories into valuation, risk, and narrative frameworks investors can use. Written by Hartaj Singh, a biotech analyst focused on translating innovation into investment reality.
You can find recent issues that have been published by The Biotech Capital Compass on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to The Biotech Capital Compass, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Biotech Capital Compass as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Biotech Capital Compass using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like The Biotech Capital Compass. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.